Descripción corta
Looking to diversify your portfolio with future-shaping ventures? We’ve done the homework for you! After reviewing 90+ equity crowdfunding platforms, we’ve handpicked some of the most exciting early-stage startups across Europe that are open to investment — with entry points starting from just a few hundred euros.
Looking to diversify your portfolio with future-shaping ventures? We’ve done the homework for you! After reviewing 90+ equity crowdfunding platforms, we’ve handpicked some of the most exciting early-stage startups across Europe that are open to investment — with entry points starting from just a few hundred euros.
SERVATRIX on Capital Cell
SERVATRIX Biomed is a spin-off from the Autonomous University of Madrid (UAM) and the Spanish National Research Council (CSIC) dedicated to developing advanced treatments for fatty liver disease, particularly non-alcoholic steatohepatitis (NASH), and its progression to liver fibrosis and cirrhosis.
Estimated return of 2500% with potential exit in 2030
Industry - HealtTech
Raising- 550.000 EUR
Valuation (pre-money) - 2.600.000 EUR
Company and product stage - Prototype/preclinical
What problem SERVATRIX is solving?
Fatty liver disease is caused by fat accumulation and inflammation potentially leading to fibrosis and cirrhosis. It is not a single condition but results from metabolic, environmental, and genetic factors driving chronic oxidative and inflammatory stress. Affecting 25% of the global population, NASH causes over 2 million deaths annually and more than 70 million cases progress to cirrhosis. With no approved treatment, it has become the leading cause of liver transplants in the US, representing a major and growing public health concern.
SERVATRIX take a new approach to treating NASH, viewing it as a symptom of underlying conditions like altered metabolism, chronic inflammation and fibrosis. SERVATRIX therapy targets these causes by activating NRF2, a protein that controls the expression of multiple mechanisms of organ protection, ultimately restoring cellular balance. SERVATRIX patented strategy and molecules safely maintain NRF2 at physiological levels, reducing oxidative and metabolic stress. In preclinical models, this strategy has demonstrated to offer a promising strategy by halting NASH progression and its complications.
What is SERVATRIX market potential?
The increasing number of diagnosed cases, driven by the use of biomarkers and non-invasive techniques, combined with a deeper understanding of the disease and its mechanisms, is fueling the rapid growth of the NASH therapy market. With a current market value of approximately $3.53 billion in 2023, it is projected to reach $77.42 billion by 2031, growing at a compound annual growth rate (CAGR) of 47.10% (Figure 4). This presents a critical unmet medical need and a significant market opportunity, positioning the NASH/MASH sector as one of the most lucrative in biotech.
Bene Bono on Tudigo
Bene Bono is the benchmark for anti-waste shopping. Every week, we deliver delicious products saved from waste at discounted prices.
Estimated return of up to 420%
Industry - FoodTech
Company and product stage -+30,000 regular customers
What problem Bene Bono is solving?
Food waste represents a major economic and environmental challenge. Every year, more than €130 billion worth of food is wasted in Europe, much of it during processing and distribution.
Consumer trends confirm the emergence of a structuring market.
Bene Bono is the established leader in France in the anti-waste online shopping segment, positioning itself in a growing and differentiating segment, at the intersection of anti-waste platforms (Too Good To Go, Phenix).
Bene Bono relies on a unique model combining subscription, personalization and logistics optimization to offer consumers an efficient and accessible alternative.
- A win-win operation : low prices, very strong customer loyalty, and a no-commitment model.
- An optimized supply chain : an advanced infrastructure that guarantees smooth management of unsold items and efficient delivery in 6 regions, and soon throughout France.
- A wide and expanding range : 1000 products ranging from fruits and vegetables, to hygiene and cleaning products, including groceries, drinks and fresh produce.
- A strong environmental impact : more than 7 million kilos of products saved since launch.
What isBene Bono market potential?
10 million tons of food are wasted each year in France, representing an economic loss of 16 billion euros. In Europe, food waste represents a market worth 130 billion euros per year.
Hybrid Air Vehicles on Crowdcube
On a mission to revolutionise the aerospace industry, Airlander is the world's first full-scale hybrid airship, which offers ultra-low emissions and dual-use capabilities for a better-connected tomorrow. Airlander’s innovative capabilities unlock potential opportunities in eco-tourism, regional passenger transport, communication & surveillance, and logistics.
Company and product stage - Airlander 10 has completed multiple successful full-scale flights, with £140m invested to date.
Industry - aerospace
Valuation (pre-money) - 81,000,000 GBP
What problem Hybrid Air Vehiclesis solving?
Problem
Today’s transportation gives you the options of fast, energy intensive, and costly air services or much slower, infrastructure-dependent alternatives. This gap in the market forces service users to consistently make compromises.
Solution
Airlander is designed to be a dual use, cost efficient aircraft aiming to deliver up to 90% fewer emissions than alternate aircraft, with a path to zero-emissions. Unrestricted by traditional infrastructure and targeting up to five days endurance, Airlander offers an innovative solution to address the market gap.
What is Hybrid Air Vehicles market potential?
Our calculations estimate a $750bn pa transport equipment market, outlining the vast opportunity space for Airlander. We anticipate significant market growth as aviation transitions to net zero and the defence industry looks to innovative new technology to resolve their operational challenges.
Honest Mobile on Crowdcube
Honest is the mobile network doing things differently. Our Classic SIM shook things up with bills that drop, carbon-negative plans and support in seconds. Now our Smart SIM is helping to make bad signal and expensive roaming a thing of the past – backed by record customer growth in 2024 and 20,000+ customers.
Company and product stage - 85,000+ sign ups to Smart SIM waiting list before this launched.
Industry - Communication
Raising - 500,000 GBP
Valuation (pre-money) - 15,000,000 GBP
What problem Honest Mobile is solving?
Problem
For too long, the big mobile networks have taken advantage, giving customers unreliable signal, expensive roaming, annual price hikes and more. We built Honest as a new kind of mobile network – one that actually cares about the same stuff you do.
Solution
Our everyday Classic SIM includes bills that drop every month, the UK’s fastest 5G and support in seconds. Meanwhile, our Smart SIM lets you connect to every UK network and roam free in 180+ countries – no more bad signal or expensive roaming.
What is Honest Mobile market potential?
Company helping to drag the US$1.14 trillion telecoms industry into the future. In 2024, we doubled our customer base within six months and have more than 20,000 customers.
Giles on SeedBlink
AI Agent for Faster and Easier Clinical, Medical & Healthcare Research
Industry - AI / HealtTech
Raising - 741.017 EUR
Company and product stage - Active onboarding of clients across academia, enterprise healthcare, and government organizations.
What problem Giles is solving?
The Problem: Healthcare research is plagued by being manually intensive, inefficiencies and data fragmentation, costing businesses massively:
- Costly Inefficiencies: Inefficiencies in global research waste $170B annually.
- Not using AI for Clinical Trials – Inflates project costs by min 25%
- Lack of AI adoption in the US Healthcare system as a whole – Costs $360B pa
- AI Adoption Gap: Despite 98% of healthcare organizations having an AI strategy, 92% of internal AI projects fail due to a lack of expertise.
- Data Overload: Dispersed datasets across multiple platforms create manual-intensive bottlenecks in research and regulatory compliance.
- Delayed Market Response: High costs and extended research cycles hinder organizations from scaling and capitalizing on new market opportunities.
Giles, is the conversation AI-powered research assistant designed for clinical, medical, and healthcare professionals. By integrating advanced AI-driven insights with internal and external data sources, giles® transforms research workflows by:
Connecting to critical databases such as PubMed, FDA, ClinicalTrials.gov, Medline, NICE, MHRA, Embase, and Cochrane.
Enabling seamless document processing via integration with Outlook, Jira, and local documents.
Providing LLM-agnostic adaptability, allowing organizations to select their preferred AI models.
What is Giles market potential?
giles® targets the $90B HealthTech AI market as part of the $390B HealthTech sector.
With our partner and lead investor, Regulatory Scientific & Health Solutions (R-S-S), capturing 0.1% ($90M) of the market puts us on track for a $1B+ valuation within four years.
Opportunities exist in clinical trials, regulatory affairs, drug development, health technology assessments, licensing, healthcare productivity and beyond.
biaNergy on Spreds
Transfers the electricity on-air to devices - without any physical connection, wirelessly
Industry - FoodTech
Raising - 2,500,000 EUR
Valuation (pre-money) - 7,500,000 EUR
What problem biaNergy is solving?
biaNergy has developed Magnetic Resonance Technology - Extended, a wireless electricity system that works just like Wi-Fi but for power. No more cables. No more plugging in. No more battery waste. And you can afford to forget your cord or power bank safely at home!
It is time for opening avenues to new technologies: Imagine cardiac pacemakers would be energized wirelessly without the need for an open operation on the patient due drained battery, or your reading lamp unchained, moving freely on the floor. Imagine a building without extensive wall-wiring. A transmitter as small as a wi-fi modem propagates energy safely, without any harm to living beings and objects in homes, offices, trains, busses, cars, cafés and public places..
TALK-N-JOB on Companisto
Award-winning ConversationalAI application for the future of job applications, with international growth and renowned partners such as NHS and SAP.
Estimated return of 338%
Company and product stage - 150 SaaS clients
Industry - HRTECH
Raising - 1,350,000 EUR
Valuation (pre-money) - 6,500,000 EUR
Company and product stage - €1.1M ARR, 150 SaaS clients, 20+ ATS integrations,
What problem TALK-N-JOB is solving?
Traditional job applications—resumes, cover letters, long forms—are a turnoff for many frontline and blue-collar workers. As a result, companies miss out on a massive talent pool that doesn’t engage with outdated hiring systems.
Talk’n’Job tackles this by offering voice-based, mobile-first job applications. Candidates can apply simply by talking—no resumes, no downloads, no forms. With just a scan or click, they enter a fully automated voice interview, available in multiple languages.
This radically accessible process delivers results:
40% more candidates,
faster hiring,
up to 80% less media spend.
What is TALK-N-JOB market potential?
The market opportunity is huge:
€18.1B in the EU,
€17.8B in the U.S.,
with a serviceable obtainable market of over €70M in DACH alone.
Talk’n’Job is positioned to lead a new category of recruitment tech, targeting industries like retail, logistics, and hospitality.
Lighthouse Biotech on CrowdFundMe
Liquid biopsy technology to isolate live circulating tumor cells, providing high-quality biological material for oncology research and precision medicine.
Industry - HealtTech
Raising - 800.000 EUR
Valuation (pre-money) - 9.000.000 EUR
Company and product stage - Revenue growth forecast from €400K in 2025 to €2M in 2029
Project and business model description of Althink
Lighthouse Biotech is a cutting-edge startup in oncology diagnostics, focused on personalizing cancer treatment through a minimally invasive solution. Its flagship innovation, the DropH device, is the first metabolic liquid biopsy that isolates live circulating tumor cells (CTCs) from a simple blood sample—overcoming limitations of traditional methods.
Leveraging nanotechnology and inspired by Otto Warburg’s discoveries, DropH detects tumor cells by analyzing their metabolic acidity. Like a PET scan at the cellular level, it distinguishes cancerous cells from healthy ones with high precision.
Beyond detection, DropH also monitors immune response, offering a powerful dual diagnostic tool to enhance treatment outcomes.
The liquid biopsy market is booming, with a projected compound annual growth rate (CAGR) of 11.60% through 2030 , driven by the growing demand for non-invasive diagnostic solutions and technological innovation. Lighthouse Biotech is strategically positioned in this landscape as a pioneer in metabolic liquid biopsy , offering a unique solution to identify and isolate live and intact circulating tumor cells (CTCs). This technology addresses a critical need in the global oncology industry , making the company a unique investment opportunity in a rapidly evolving market.
DaiOff on DOZEN INVESTMENTS
Revolutionizing labor compliance with Artificial Intelligence
Industry - AI / HRTECH
Raising - 800,000 EUR
Valuation (pre-money) - 6,000,000 €
What problem DaiOff is solving?
DaiOff uses AI to revolutionize labor compliance, adapting it to the demands of the 21st century in an environment of increasing regulatory pressure. Its platform, designed for unions, workers, and companies, acts as a "360° virtual lawyer ," optimizing up to 70% of the necessary resources and providing automated legal advice powered by machine learning.
What is DaiOff market potential?
Unlike DaiOff, most LegalTech solutions on the market are too general and don't adapt to the specifics of labor law, a sector that generates more than €10 billion annually globally in legal services alone.
This gives it a technological advantage and a strong market position , with the ability to grow and adapt to other areas of law thanks to the adaptability of its technology.
Don’t miss out on amazing investment opportunities follow us on LinkedIn or Facebook and learn more about crowdfunding on Crowdinform.com
We wish you a good day and successful investing!
CrowdInform
